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Abstract
Growing bacterial resistance in Gram-positive pathogens means that what were once effective and inexpensive treatments for infections
caused by these bacteria are now being seriously questioned, including penicillin and macrolides for use against pneumococcal infections
and—in hospitals—oxacillin for use against staphylococcal infections. As a whole, multidrug-resistant (MDR) Gram-positive pathogens
are rapidly becoming an urgent and sometimes unmanageable clinical problem. Nevertheless, and despite decades of research into the
effects of antibiotics, the actual risk posed to human health by antibiotic resistance has been poorly deﬁned; the lack of reliable data
concerning the outcomes resulting from antimicrobial resistance stems, in part, from problems with study designs and the methods used
in resistence determination. Surprisingly little is known, too, about the actual effectiveness of the many types of intervention aimed at
controlling antibiotic resistance. New antibiotics active against MDR Gram-positive pathogens have been recently introduced into clinical
practice, and the antibiotic pipeline contains additional compounds at an advanced stage of development, including new glycopeptides,
new anti-methicillin-resistant Staphylococcus aureus (MRSA) b-lactams, and new diaminopyrimidines. Many novel antimicrobial agents are
likely to be niche products, endowed with narrow antibacterial spectra and/or targeted at speciﬁc clinical problems. Therefore, an
important educational goal will be to change the current, long-lasting attitudes of both physicians and customers towards broad-spec-
trum and multipurpose compounds. Scientiﬁc societies, such as the European Society of Clinical Microbiology and Infectious Diseases
(ESCMID), must play a leading role in this process.
Antibiotic resistance is now acknowledged as a major public
health issue, affecting virtually all major bacterial pathogens
and spreading to all types of nosocomial settings as well as
the community at large [1,2].
Resistance is now documented in bacteria that, tradition-
ally, were fully susceptible. In addition, multidrug-resistant
(MDR) bacteria have risen to prominence, and new ‘oppor-
tunistic’, and often MDR, organisms are recognized increas-
ingly as important pathogens in both the nosocomial and
community settings.
Europe has been at the forefront of efforts to study and
control antimicrobial resistance, and this has prompted
numerous recommendations for action at both national and
international levels [3,4].
Notwithstanding these worthy initiatives, the measures
currently underway in Europe to prevent and control resis-
tance to antimicrobial agents are far from sufﬁcient, and the
consequences for public health threaten to become acute
and have come to have a highly visible impact within only a
short space of time.
One of the major therapeutic challenges is, without doubt,
multidrug resistance in Gram-positive pathogens. Growing
bacterial resistance means that what were once effective and
inexpensive treatments for infections caused by Gram-posi-
tive pathogens are now being seriously questioned, including
penicillin and macrolides for use against pneumococcal infec-
tions and—in hospitals—oxacillin for use against staphylococ-
cal infections.
Multidrug resistance problems are related, at least in part,
to the international dissemination of epidemic clones that have
accumulated several resistance traits through an evolutionary
process. Numerous molecular epidemiological surveys have
outlined the widespread expansion in Europe of antibiotic-
resistant clones of Gram-positive organisms such as penicillin-
resistant pneumococci, methicillin-resistant Staphylococcus
aureus (MRSA), and vancomycin-resistant enterococci [5–7].
A better understanding of the molecular epidemiology of
MDR Gram-positive pathogens is thus central to all efforts
aimed at controlling resistance [8]. Research has been facili-
tated in recent years by advances in genetic analysis, multilo-
cus sequence typing being an unambiguous and highly
discriminatory method for characterizing (or ‘genotyping’)
isolates according to speciﬁc DNA sequences [9].
The international spread of MRSA in hospitals [2] is a
major concern, widely echoed even in the lay press [10].
Recently, considerable epidemiological research has been
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directed at the spread of MRSA in the community setting
also, arising independently of local nosocomial strains [11].
Epidemiological data are also providing evidence of the
growing importance of enterococci, and most notably Entero-
coccus faecium, as nosocomial pathogens, possibly following the
expansion of the vancomycin-resistant clonal lineage CC17 [6].
As far as pneumococci are concerned, the resistance
trends vary throughout Europe for both penicillin and mac-
rolide resistance, but a worrisome increasing trend towards
dual non-susceptibility is being observed in many countries
[2]. Although the increasing diffusion of antipneumococcal
vaccination is expected to affect the resistance picture dra-
matically, the potential for capsule switch among currently
circulating invasive pneumococci must be seriously consid-
ered [12]. Worthy of note is the fact that the new conjugate
vaccine does not cover serogroups in which antibiotic resis-
tance is quite common in Europe [2].
As a whole, MDR Gram-positive pathogens are rapidly
becoming an urgent and sometimes unmanageable clinical
problem, not only in pneumonology, oncology and urology
wards, but also in intensive-care units. Mortality has
increased among intensive-care patients, where infections are
resistant to ﬁrst-line and second-line empirical therapies. The
presence of MDR Gram-positive bacteria has been variously
associated with increased rates of re-operation, surgical site
infection and abscess formation in intra-abdominal infections.
Nevertheless, and despite decades of research into the
effects of antibiotics, the actual risk posed to human health by
antibiotic resistance has been poorly deﬁned [13], and infor-
mation on this is of the utmost importance to enable health
system administrators, policy-makers and healthcare workers
to prioritize, develop and implement solutions to the problem.
Sometimes, the perverse clinical consequences of antimi-
crobial resistance have been deliberately denied, with a pos-
sible eye to preserving antibiotic sales, as was the case
during the sharp increase in macrolide resistance occurring
among pneumococci in the 1990s [14].
Research to quantify the clinical impact of resistance poses
a major challenge. Outcomes to be considered include not
only clinical endpoints (e.g. morbidity, mortality, and length
of hospital stay), but also economic endpoints, such as the
costs of newer, more expensive antibiotics, additional tests,
and lengthier hospital stays associated with infections due to
antibiotic-resistant bacteria.
The lack of reliable data concerning the outcomes result-
ing from antimicrobial resistance stems, in part, from prob-
lems with the study designs and methods used in their
determination [13,15].
No theoretical approach involving a long-term ecological
experiment to assess the risk/beneﬁt ratio of antibiotic
consumption has ever been undertaken, among other rea-
sons because of the wide range of confounding variables.
Studies investigating the consequences of infections caused
by antibiotic-resistant organisms in the community setting
are even more demanding, and such data are few and far
between.
Surprisingly little is known, too, about the actual effective-
ness of the many types of interventions aimed at controlling
antibiotic resistance. Alongside a number of encouraging
experiences in which interventions have been associated with
a reduction in resistance rates, there is a lack of good-quality
data indicating that widespread effects can be achieved or
maintained [16]. Researchers in the UK, who have systemati-
cally evaluated interventions to improve antibiotic prescribing
in hospitals, found good evidence that reductions in antibi-
otic usage can reduce resistance in multiply resistant Gram-
negative bacilli. However, there is far less evidence of the
effectiveness of these kinds of measures in controlling MRSA
or vancomycin-resistant enterococci [17]. A review of isola-
tion policies for the management of MRSA conducted by
researchers at various UK centres also provided limited
evidence of the effectiveness of single-room isolation and
cohorting measures, and conﬂicting evidence of the effective-
ness of isolation wards [18]. It is worth noting that the
overwhelming majority of intervention studies reviewed had
to be excluded from the analysis because of an uncontrolled
‘before and after’ design, the collection of an inadequate time
series, or various other methodological ﬂaws, indicating an
unacceptable waste of research resources.
Efforts to improve antibiotic prescribing in hospitals and
isolation policies in the hospital management of MDR Gram-
positive pathogens will certainly have to play a major role in
controlling the spread of these organisms, and such efforts
are currently attracting substantial ﬁnancial and intellectual
resources. Yet, the greatest cause of concern, both in daily
practice and in a longer-term perspective, is the increasing
scarcity and inadequacy of therapeutic resources.
Despite the pressing need for new antibiotics, industrial
research in this area is steadily declining; of the candidate
drugs currently under development by pharmaceutical com-
panies, only a few are antibiotics [19,20]. Having said this,
we should also acknowledge that the development of new
antimicrobial agents over the last 10 years has been charac-
terized by a relatively greater degree of activity in the ﬁeld
of antibiotics active against Gram-positive bacteria, the main
reason for this being the rapid increase in, and great atten-
tion paid to, infections caused by MDR organisms.
This has led to the recent introduction of new antibiotics
active against MDR Gram-positive pathogens into clinical
practice, and the antibiotic pipeline contains additional com-
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pounds at an advanced stage of development, including new
glycopeptides, new anti-MRSA b-lactams, and new diamino-
pyrimidines [21].
It cannot be too strongly emphasized that there is an
urgent need for new antibacterial agents. Despite all our
efforts, no new antibiotics under clinical development or
undergoing preclinical evaluation can satisfactorily meet the
new and important challenges already clearly emerging in
current medical practice, needs that will probably become
increasingly pressing in the near future [22].
Many novel antimicrobial agents active against MDR Gram-
positive pathogens are likely to be niche products, endowed
with narrow antibacterial spectra and/or targeted at speciﬁc
clinical problems. Therefore, an important educational goal will
be to change the current, long-lasting attitudes of both physi-
cians and customers towards broad-spectrum and multipur-
pose compounds. Scientiﬁc societies, such as the European
Society of Clinical Microbiology and Infectious Diseases (ESC-
MID), must play a leading role in this process.
ESCMID co-organized, in conjunction with the DG
Research of the European Commission, a conference entitled
‘The Role of Research in Combating Antibiotic Resistance’
(28–30 November 2003), held in Rome under the Patronage
of the Italian government [22], and is currently convening
several conferences on resistance of various microorganisms
and in various settings [23,24].
The purpose of this theme section is to highlight and dis-
cuss the current problems, including molecular and pathoge-
netic aspects of infections caused by Gram-positive
pathogens as well as diagnostic and therapeutic strategies for
their management, based on the presentations delivered at a
recent ESCMID Conference on this subject (Venice, Italy,
May 29–31 2008).
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